Using nanoparticles to improve influenza vaccines
Biomimetic nanoparticles to enhance the breadth of influenza vaccines
This study is testing a new flu vaccine that uses tiny particles to help your body fight off different strains of the virus, aiming to give you better protection and possibly reduce the need for yearly shots.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10889024 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of influenza vaccine that can provide broader protection against various strains of the virus, including those that may cause pandemics. The approach involves using biomimetic nanoparticles that encapsulate a specific immune-stimulating agent, which enhances the body's immune response. By combining this novel adjuvant with an inactivated flu vaccine, the researchers aim to stimulate a strong and rapid immune response that can protect against multiple flu virus subtypes. This could potentially reduce the need for annual vaccine updates and improve overall vaccine effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for influenza complications, such as the elderly, young children, and those with underlying health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received a flu vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a universal flu vaccine that offers better protection against seasonal and pandemic influenza strains.
How similar studies have performed: Other research has shown promise in using novel adjuvants and nanoparticle technology to enhance vaccine efficacy, indicating that this approach could be viable.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Wu, Mei X — Massachusetts General Hospital
- Study coordinator: Wu, Mei X
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.